keyword
https://read.qxmd.com/read/38652891/adalimumab-dose-reduction-and-withdrawal-in-stable-non-infectious-pediatric-uveitis-an-open-label-prospective-pilot-study
#1
JOURNAL ARTICLE
P D Yuan, Y W Hu, X Q Chen, G Y Chen, Y Pan, H Y Lao, D Liang
PURPOSES: This study investigated the feasibility of adalimumab (ADA) dose reduction and withdrawal strategy in children with stable pediatric non-infectious uveitis (PNIU). METHODS: This open-label prospective pilot trial recruited 18 stable PNIU patients (33 eyes) between two and eighteen years old who were treated with standard doses of ADA (20/40 mg every 2 weeks) plus oral methotrexate. The interval of ADA injection was extended to 4 weeks and followed up for 24 weeks...
April 23, 2024: Ocular Immunology and Inflammation
https://read.qxmd.com/read/38651202/detection-of-significant-liver-fibrosis-in-chinese-psoriasis-patients-receiving-methotrexate-a-comparison-between-transient-elastography-and-liver-histology
#2
JOURNAL ARTICLE
C S M Wong, L L Y Mak, V K H Lee, R C L Lo, M M H Chung, F Chu, C K Yeung, M F Yuen, H H L Chan
INTRODUCTION: Methotrexate (MTX) is effective for treating psoriasis and psoriatic arthritis, but its potential hepatoxicity remains a concern. Liver biopsy, the gold standard for detecting MTX-induced liver injury, is invasive and carries considerable risk. Transient elastography (TE) offers a non-invasive alternative for detecting advanced liver fibrosis. This study investigated the performance of TE in detecting MTX-induced liver fibrosis among Chinese psoriasis patients, compared with liver biopsy...
April 2024: Hong Kong Medical Journal
https://read.qxmd.com/read/38632138/comparison-of-old-and-new-systemic-treatments-for-moderate-to-severe-atopic-dermatitis
#3
REVIEW
Hyun J Yim, Tiffany Jean, Peck Y Ong
PURPOSE OF REVIEW: Historically, systemic treatments for atopic dermatitis (AD) primarily consisted of immunosuppressive agents such as corticosteroids and Disease Modifying Antirheumatic Drugs (DMARDS), which provided symptomatic relief but often had long-term adverse effects. Newer treatments have shown significant efficacy with less side effects in clinical trials. This review discusses and compares conventional and newer systemic treatments for AD. RECENT FINDINGS: Newer medications for AD including dupilumab, tralokinumab, lebrikizumab, and oral JAK inhibitors have been shown to be safe and efficacious...
April 18, 2024: Current Allergy and Asthma Reports
https://read.qxmd.com/read/38621925/-effect-and-mechanism-of-aqueous-extract-of-strychni-semen-on-bone-destruction-in-rats-with-type-%C3%A2-collagen-induced-rheumatoid-arthritis
#4
JOURNAL ARTICLE
Xin-Zhuo Zhang, Xiao-Hui Su, Shi-Qi Kang, Bei Yuan, Jing-Hang Yang, Na Lin, Xiang-Ying Kong, Feng Huang
To investigate the mechanism of action of aqueous extract of Strychni Semen(SA) on bone destruction in rats with type Ⅱ collagen-induced arthritis(CIA), the SD rats were randomly divided into normal group, model group, low, medium, and high dose(2.85, 5.70, and 11.40 mg·kg~(-1)) groups of SA, and methotrexate group. Except for the normal group, the CIA model was prepared for the other groups. After the second immunization, different doses of SA were given to the low, medium, and high dose groups of SA once a day, and the methotrexate group was given once every three days...
March 2024: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://read.qxmd.com/read/38618451/a-rare-case-of-extranodal-natural-killer-t-cell-lymphoma-nasal-type-associated-with-hemophagocytic-lymphohistiocytosis-in-a-patient-with-recurrent-sinusitis
#5
Bryce R Christensen, Chung-Ting J Kou, Lauren E Lee
We present a rare case of hemophagocytic lymphohistiocytosis (HLH) secondary to nasal-type extranodal natural killer/T-cell lymphoma (ENKL). Nasal-type ENKL is a rare subtype of non-Hodgkin's lymphoma usually associated with Epstein-Barr virus (EBV). The patient was a 19-year-old woman who presented with facial numbness, diminished hearing, and dysgeusia. She was febrile with palatal necrosis, loss of gag reflex, and cranial nerve palsies. Labs revealed neutropenia. Broad-spectrum antimicrobials, including amphotericin, were started...
March 2024: Curēus
https://read.qxmd.com/read/38616308/frontline-combination-of-dasatinib-and-low-intensity-chemotherapy-in-adults-with-de-novo-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia
#6
JOURNAL ARTICLE
Yizhou Peng, Jinjin Huang, Jin Yin, Fankai Meng, Yang Cao, Liang Huang, Dengju Li, Yicheng Zhang, Donghua Zhang, Li Meng, Zhiqiang Han, Zhenya Hong
BACKGROUND: Studies on dasatinib-based low-intensity induction regimens and post-remission strategies are limited in China. Therefore, we conducted a single-center phase 2 trial in newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) to establish the efficacy and safety of this treatment approach. RESEARCH DESIGN AND METHODS: Patients received one month of dasatinib plus low-intensity chemotherapy and two months of dasatinib monotherapy for induction, followed by a single course of high-dose methotrexate for consolidation...
April 14, 2024: Expert Review of Hematology
https://read.qxmd.com/read/38607071/a-novel-approach-for-glioblastoma-treatment-by-combining-apoptosis-inducers-tmz-mtx-and-cytarabine-with-e-v-a-eltanexor-venetoclax-and-a1210477-inhibiting-xpo1-bcl-2-and-mcl-1
#7
JOURNAL ARTICLE
Kai Zhao, Madita Braun, Leonie Meyer, Katharina Otte, Hartmann Raifer, Frederik Helmprobst, Vincent Möschl, Axel Pagenstecher, Hans Urban, Michael W Ronellenfitsch, Joachim P Steinbach, Jelena Pesek, Bernhard Watzer, Wolfgang A Nockher, R Verena Taudte, Andreas Neubauer, Christopher Nimsky, Jörg W Bartsch, Tillmann Rusch
Adjuvant treatment for Glioblastoma Grade 4 with Temozolomide (TMZ) inevitably fails due to therapeutic resistance, necessitating new approaches. Apoptosis induction in GB cells is inefficient, due to an excess of anti-apoptotic XPO1/Bcl-2-family proteins. We assessed TMZ, Methotrexate (MTX), and Cytarabine (Ara-C) (apoptosis inducers) combined with XPO1/Bcl-2/Mcl-1-inhibitors (apoptosis rescue) in GB cell lines and primary GB stem-like cells (GSCs). Using CellTiter-Glo® and Caspase-3 activity assays, we generated dose-response curves and analyzed the gene and protein regulation of anti-apoptotic proteins via PCR and Western blots...
April 4, 2024: Cells
https://read.qxmd.com/read/38604797/-clinical-study-of-15-cases-of-primary-non-immunodeficient-central-nervous-system-lymphoma-in-children
#8
JOURNAL ARTICLE
H X Gao, N N Zhang, C J Zhou, L Jin, J Yang, S Huang, M Zhang, N Li, Y H Zhang, Y L Duan
Clinical data of 15 primary central nervous system lymphoma (PCNSL) children aged ≤18 years admitted to our hospital between May 2013 to May 2023 were retrospectively analyzed. Our goal was to summarize the clinical features of children and investigate the therapeutic effect of a high-dose methotrexate (HD-MTX) based chemotherapy regimen on this disease. The male-to-female ratio was 2.7∶1, and the median age was 7.2 (2.3-16.4) years at diagnosis. The initial clinical symptoms were primarily cranial hypertension, with imaging findings revealing multiple lesions...
February 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38590596/primary-central-nervous-system-lymphoma-treatment-outcomes-10-year-experience-single-center-study
#9
JOURNAL ARTICLE
Ajla Nizic, Lejla Ibricevic-Balic, Timur Ceric, Ibrahim Omerhodzic, Lejla Burazerovic, Vasvija Saric, Emina Mameledzija, Berina Hasanefendic
BACKGROUND: Primary central nervous system lymphoma(PCNSL) is an aggressive, rare form of Non-Hodgkin lymphoma, characterized by the absence of systemic disease. There are limited data and no strictly defined guidelines for management of PCNSL. OBJECTIVE: The aim of this study was to report a 10 year experience of PCNSL treatment, to evaluate treatment outcomes and asses Progression Free and Overall Survival of these patients. METHODS: Study was conducted on the Haematology Clinic, Clinical center University of Sarajevo, BH, in the period from January 2012...
2024: Materia Socio-medica
https://read.qxmd.com/read/38581718/clinical-outcomes-of-etoposide-and-cytarabine-as-consolidation-in-elderly-patients-with-primary-cns-lymphoma
#10
JOURNAL ARTICLE
Yu Ri Kim, Hyunsoo Cho, Soo-Jeong Kim, Haerim Chung, Hye Won Kook, Ji Eun Jang, June-Won Cheong, Jin Seok Kim
BACKGROUND: A consolidation strategy has not been established for transplant-ineligible elderly patients with primary central nervous system lymphoma (PCNSL). In this study, we aimed to retrospectively evaluate the clinical outcomes of etoposide and cytarabine (EA) as consolidation chemotherapy for transplant-ineligible patients with PCNSL following high-dose methotrexate (MTX)-based induction chemotherapy. MATERIALS AND METHODS: Between 2015 and 2021, newly diagnosed transplant-ineligible patients with PCNSL with diffuse large B-cell lymphoma were consecutively enrolled...
April 6, 2024: Oncologist
https://read.qxmd.com/read/38576595/high-dose-methotrexate-and-zanubrutinib-combination-therapy-for-primary-central-nervous-system-lymphoma
#11
EDITORIAL
Budhi Singh Yadav
In this editorial I comment on the article, published in the current issue of the World Journal of Clinical Oncology . Primary central nervous system lymphoma (PCNSL) is a disease of elderly and immunocompromised patients. The authors reported clinical results of 19 patients with PCNSL treated with zanubrutinib/high dose methotrexate (HD-MTX) until disease progression. They demonstrated that the combination of zanubrutinib with HD-MTX led to a marked clinical response and tolerability among these patients. They also observed that cerebrospinal fluid liquid biopsy to detect circulating tumor DNA may be a good option for evaluating treatment response and tumor burden in patients with PCNSL...
March 24, 2024: World Journal of Clinical Oncology
https://read.qxmd.com/read/38575193/detecting-high-dose-methotrexate-induced-brain-changes-in-pediatric-and-young-adult-cancer-survivors-using-18-f-fdg-pet-mri-a-pilot-study
#12
JOURNAL ARTICLE
Lucia Baratto, Shashi B Singh, Sharon E Williams, Sheri L Spunt, Jarrett Rosenberg, Lisa Adams, Vidyani Suryadevara, Michael Iv, Heike Daldrup-Link
Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [18 F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors. Methods: In this prospective, single-center pilot study, 10 children and young adults with sarcoma ( n = 5), lymphoma ( n = 4), or leukemia ( n = 1) underwent dedicated brain [18 F]FDG PET/MRI and a 2-h expert neuropsychologic evaluation on the same day, including the Wechsler Abbreviated Scale of Intelligence, second edition, for intellectual functioning; Delis-Kaplan Executive Function System (DKEFS) for executive functioning; and Wide Range Assessment of Memory and Learning, second edition (WRAML), for verbal and visual memory...
April 4, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38569859/-successful-bridging-therapy-with-alectinib-prior-to-allogeneic-stem-cell-transplantation-for-refractory-alk-positive-anaplastic-large-cell-lymphoma
#13
JOURNAL ARTICLE
Asuka Kono, Keisuke Tanaka, Tomohito Shimada, Kana Bando, Atsushi Takahata, Satoshi Koi, Masahide Yamamoto, Takehiko Mori, Shigeo Toyota
Although alectinib is effective for relapsed or refractory ALK-positive anaplastic large cell lymphoma (ALCL) and has a favorable safety profile, its role as a bridging therapy for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and the role of allo-HSCT itself in this setting are unknown. A 35-year-old man with ALK-positive ALCL experienced relapse after first-line therapy with CHOP. Brentuximab vedotin led to partial response and high-dose chemotherapy combined with autologous HSCT was performed...
2024: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://read.qxmd.com/read/38559593/involvement-of-the-abcb1-c3435t-variant-but-not-the-mthfr-c677t-or-mthfr-a1298c-variant-in-high-dose-methotrexate-induced-toxicity-in-pediatric-acute-lymphoblastic-leukemia-patients-in-china
#14
JOURNAL ARTICLE
Qie Guo, Jia-Lin Sun, Ran Li, Xiao Li
PURPOSE: It remains unclear whether the MTHFR C677T, MTHFR A1298C and ABCB1 C3435T genetic variants are associated with methotrexate (MTX) elimination delay and high-dose MTX (HD-MTX) toxicities in the treatment of pediatric acute lymphoblastic leukemia (ALL). The aim of our study was to analyze the potential predictive role of MTHFR C677T, MTHFR A1298C and ABCB1 C3435T in toxicities and the relationship between these variants and MTX elimination delay during HD-MTX therapy in pediatric ALL patients...
2024: International Journal of General Medicine
https://read.qxmd.com/read/38543908/impact-of-immunomodulatory-therapy-on-covid-19-vaccine-response-in-patients-with-autoimmune-inflammatory-rheumatic-diseases
#15
REVIEW
Ruth Xian Lynn Yap, Yi Wye Lai, Chang Wei, Joel Jia Wei Ng, Dan Xu, Shuo Feng, Rong Mu, Bernard Yu-Hor Thong, Chuanhui Xu
Coronavirus disease 2019 (COVID-19) vaccination is essential for patients with autoimmune inflammatory rheumatic diseases (AIIRD) to reduce the risk of morbidity and mortality associated with serious COVID-19 infection. With endemicity, waning of vaccine- and infection-acquired immunity, and development of SARS-CoV-2 variants, the need for additional doses of vaccines against serious illness in high-risk immunocompromised persons remains imperative. This review examines how immunomodulatory therapies affect vaccine-induced immune response in patients with AIIRD...
March 6, 2024: Vaccines
https://read.qxmd.com/read/38525397/the-effect-of-dextrose-hypotonic-vs-saline-hydration-on-methotrexate-induced-nephrotoxicity-in-male-and-female-rats
#16
JOURNAL ARTICLE
Zahra Hasanpour, Samira Choopani, Farzaneh Ashrafi, Ardeshir Talebi, Mehdi Nematbaksh
BACKGROUND: High-dose methotrexate (HDMTX) as a cytotoxic agent might cause various side effects. Hyperhydration has been implemented as the major strategy to decrease the potential risk of toxicities induced by HDMTX. This study aims to assess the renoprotective effect of hydration with dextrose water (DW) 5% versus normal saline (N/S) 0.9% against methotrexate (MTX) induced nephrotoxicity. MATERIALS AND METHODS: This experimental animal study has been conducted on 36 Wistar rats (200-250 g) categorized into six groups, including male ( n = 6) and female ( n = 6) rats receiving sodium chloride 0...
2024: Advanced Biomedical Research
https://read.qxmd.com/read/38524130/an-updated-management-approach-of-pompe-disease-patients-with-high-sustained-anti-rhgaa-igg-antibody-titers-experience-with-bortezomib-based-immunomodulation
#17
JOURNAL ARTICLE
Ankit K Desai, Garima Shrivastava, Christina L Grant, Raymond Y Wang, Trevor D Burt, Priya S Kishnani
INTRODUCTION: High sustained anti-rhGAA antibody titers (HSAT; ≥12,800) are directly linked to reduced efficacy of enzyme replacement therapy (ERT) and subsequent clinical deterioration in infantile-onset Pompe disease (IOPD). We have previously demonstrated the safety and effectiveness of a bortezomib-based immune-tolerance induction (ITI) regimen (bortezomib, rituximab, methotrexate, and IVIG) in eliminating HSAT. METHODS: Here, we describe two IOPD cases (patients 6 and 8) who developed HSAT at 8 and 10 weeks on ERT despite transient low-dose methotrexate ITI administration in the ERT-naïve setting and were treated with a bortezomib-based ITI regimen, and we compare their courses to a series of six historical patients (patients 1-5, and 7) with a similar presentation who exemplify our evolving approach to treatment...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38523896/a-rare-case-of-acute-methotrexate-toxicity-leading-to-bone-marrow-suppression
#18
Samreen Khuwaja, Matthew Lyons, Beenish Zulfiqar
Methotrexate is a first-line disease modifying antirheumatic drug used for the treatment of inflammatory arthritis. Bone marrow suppression is a common adverse reaction of methotrexate following its long-term use. However, low dose methotrexate is rarely associated with life-threatening bone marrow suppression. This case represents an atypical presentation of acute bone marrow suppression shortly after initiating treatment with low-dose methotrexate. A 76-year-old male patient presented with oral ulcers, poor oral intake, and acute kidney injury within 3 weeks of initiating 15 mg weekly of methotrexate for seronegative rheumatoid arthritis...
2024: Case Reports in Rheumatology
https://read.qxmd.com/read/38522861/successful-treatment-of-generalized-pustular-psoriasis-with-guselkumab
#19
JOURNAL ARTICLE
Martina Part
The purpose of the article: Generalized pustular psoriasis (GPP) is a rare auto-inflammatory disease. Patients with GPP may develop life-threatening complications, including sepsis, acute renal failure, neutrophilic cholangitis, high-output congestive heart failure, acute respiratory distress syndrome and death. The therapy of GPP is very limited and the course of the disease is unpredictable. Materials and methods: We report a 60-year-old woman presenting with widespread and confluent erythematous-desquamative plaques with numerous small pustules covering almost 70% of the body surface area...
December 2024: Journal of Dermatological Treatment
https://read.qxmd.com/read/38509358/-current-patient-care-of-systematic-lupus-erythematosus-in-rhineland-palatinate-and-saarland
#20
JOURNAL ARTICLE
Ciaran Alberti, Matthias Dreher, Konstantinos Triantafyllias, Andreas Schwarting
BACKGROUND: Systemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disease that is associated with great suffering for those affected, as well as high socioeconomic costs. Early diagnosis and adequate medical care are essential for a mild course of the disease. However, there is a lack of current figures and data on the care situation of patients in the area. METHODOLOGY: A total of 1546 general practitioners, rheumatologists, neurologists, nephrologists and dermatologists in Rhineland-Palatinate and Saarland were interviewed by fax or mail using a questionnaire regarding epidemiology, symptoms, therapy and therapy success...
March 20, 2024: Zeitschrift Für Rheumatologie
keyword
keyword
91529
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.